should be 73.00 to 79.00 a share this year alone.......that is my opinion
either they are changing this to ''multi exons as a class approval or it will be used for all exons as a confirmatory....that would be fantastic...its only a sequence change anyway ,the drug is the same really. So you could use this as a confirmatory first for 51 then,53 then 50 then so on .Each exon only really needs a short safety and dystrophin production check
Than 60.00 a share..many times more looking forward.
New data that confirms older trial data. will cause massive upside.
Again 2017 Sarepta will have a monster Market Cap ,they will have the only dmd treatment the works and will have all exons sealed up. Exon 53 is only 15 percent of the dmd market and worldwide 1.5 billion in treatments. add more exons add more value you would not believe .
Sarepta Therapeutic (SRPT) PT Raised to 'Street-High' $60 at Oppenheimer. April 6, 2016 6:29 AM EDT. . Oppenheimer analyst Christopher ...
CDER plans to provide a free of charge, live webcast of the April 25, 2016 meeting of the Peripheral and Central Nervous System Drugs Advisory Committee. While CDER is making a webcast available to the public for this meeting, there may be instances where the webcast transmission is not successful; staff will work to re-establish the transmission as soon as possible. Further information regarding the webcast, including the web address for the webcast, will be made available at least 2 days in advance of the meeting at the following website: .fda.gov/AdvisoryCommittees/Calendar/default.htm
CDER plans to post archived webcasts after the meeting, however, in cases where transmission was not successful, archived webcasts will not be available.
Bruce Wentworth Ph.D.
Chairman, The Science Offsite Conference, 2014
Genzyme-Sanofi Hub R&D annual conference.
Co-Leader of the 2013 Genzyme Science Offsite conference.
Group Leader, Muscle Research. Investigating various therapeutic interventions for muscle genetic diseases.
Co-founder and research leader for Medtronic-Genzyme Biotechnology, a joint venture investigating uses of cell therapy for cardiovascular disease.
Science Portfolio Leader, Cardiovascular Disease. Investigated various cell, gene, and protein therapeutic approaches for cardiovascular disease.
Keratinocyte Research Group Leader. Investigated novel concepts for keratinocyte grafting for severe burns as well as process improvements for autograft delivery.
Antisense oligonucleotides and their uses in vivo
Therapeutic development for skeletal muscle diseases
Cell based therapies for cardiovascular disease
Skin and cartilage repair-regeneration
Sarepta owns most of the patents on pmo antisense and more/ just one example here and there is many more that genzyme is getting into.
Genzyme Corporation discusses the exciting new data he and his colleagues presented on antisense therapy that is in development to treat patients with Pompe disease.
Clayton N, et al. Antisense oligonucleotide‐mediated suppression of muscle glycogen synthase 1 synthesis as an approach for substrate reduction therapy of Pompe disease.
that is how it works......................................................................................